Bristol-Myers Squibb Co.

NYSE:BMY  
64.86
-0.18 (-0.28%)
4:23:20 PM EDT: $64.81 -0.05 (-0.08%)
Equity Financing / Related

Bristol Myers Squibb Presents Analyses From Pivotal Quazar® Aml-001 Study Of Onureg In Adults With Acute Myeloid Leukemia In First Remission

Published: 12/07/2020 21:41 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb Presents Analyses From Pivotal Quazar® Aml-001 Study of Onureg® (azacitidine Tablets; Cc-486) in Adults With Acute Myeloid Leukemia in First Remission.
Bristol-myers - Analysis Showed Improved Overall Survival in Patients Independent of Number of Consolidation Treatment Cycles Received Versus Placebo.
Bristol-myers Squibb Co - Analysis Showed Treatment With Onureg Improved Overall Survival in Patients.
Bristol-myers - Results Demonstrated Treatment With Onureg Improved Overall Survival & Showed Clinical Benefit Across Other Key Secondary Endpoints.